About Noven
Noven is a company based in Miami (United States) founded in 1987 was acquired by Hisamitsu Pharmaceutical in July 2009. It operates as a Direct-to-Consumer (D2C) and Professional Services. The company has 291 employees. Noven has completed 2 acquisitions, including JDS Pharmaceuticals and JDS Therapeutics. Noven offers products and services including XELSTRYM, SECUADO, DAYTRANA, MINIVELLE, and COMBIPATCH. Noven operates in a competitive market with competitors including AbbVie, Merck, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Miami, United States
- Employees 291
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website noven.com
- Social LinkedIn X
- Acquired by Hisamitsu Pharmaceutical (Jul 2009)
- Legal Name Noven Pharmaceuticals, Inc.
- Investors
- Employee Count291
- Investments & AcquisitionsJDS Pharmaceuticals
& 1 more
- Acquired byHisamitsu Pharmaceutical
(Jul 2009)
Products & Services of Noven
Noven offers a comprehensive portfolio of products and services, including XELSTRYM, SECUADO, DAYTRANA, MINIVELLE, and COMBIPATCH.
Transdermal system for dextroamphetamine delivery in psychiatry.
Transdermal system for asenapine used in mental health.
Transdermal methylphenidate system for mental health treatment.
Estradiol transdermal system for menopausal health concerns.
Estradiol and norethindrone transdermal system for women.
Investors in Noven
Noven has secured backing from 1 investor. Prominent investors backing the company include Hisamitsu Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals and over-the-counter medications are manufactured and distributed globally. | 1834 | hisamitsu.co.jp | Tosu, Japan |
Investor details for Noven
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Noven
53 people are tracked at Noven (22 in leadership, 1 in board & advisors, 30 in team); the tracked headcount is 291.
| Name | Role | Group |
|---|---|---|
Mark Jackson | Senior Vice President, Quality & Operations | Leadership |
Alejandro D Santiago | Senior Director Of Quality | Leadership |
Dennis Pastrana Jr. | Executive Director Business Planning & Analysis | Leadership |
Juan C Fernandez | Associate Director, Facility & Security | Leadership |
Naruhito Higo | Chairman & Chief Executive Officer | Leadership |
Mario Osorio | Director IT Business Technology Services | Leadership |
Joel Lippman | Chief Operating Officer & Chief Medical Officer | Leadership |
John Choi | Vice President, Chief Financial Officer & Treasurer | Leadership |
Shinichi Sato | Vice President, Hisamitsu Group Strategy & Planning | Leadership |
Mixilexi Cata | Chief People Officer | Leadership |
Alejandro Peña | Associate Director Of Engineering | Leadership |
Amy Nenner | Chief People Officer | Leadership |
Jose Almodovar | Chief Operations And Quality Officer | Leadership |
Michael Redd | Sr Director Head Of Sales And Marketing | Leadership |
Marilyn Reynaldo | Associate Director - Talent Acquisition | Leadership |
Christina Chew | Senior Director, Business Insights And Commercial Analytics | Leadership |
Jose Sintas | Chief Research Officer | Leadership |
David J. Stade | Director, Analytical Research | Leadership |
Graciela Lopez | Director Technical Services | Leadership |
Katsumi Suzuki | Vice President, Project Lead, Hisamitsu Group R&d | Leadership |
33 more people are available in the full profile.
Complete people profiles for Noven
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Noven
Noven has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include JDS Pharmaceuticals and JDS Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Hormone-free menopause symptom relief products are developed. | jdstherapeutics.com | Purchase, United States | 2011 | Jul 2007 | •••• | |
Small molecule drugs for psychiatry and women's health are developed. | jdspharma.com | New York, United States | 2004 | Jul 2007 | •••• |
Complete acquisition details for Noven
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Noven
4 dated milestones of Noven across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Noven is founded.
- Acquisition Acquires JDS Pharmaceuticals.
- Acquisition Acquires JDS Therapeutics.
- Exit Acquired by Hisamitsu Pharmaceutical.
Competitors of Noven
Noven operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AbbVie, Merck, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| novonordisk.com | 1923 | Bagsvaerd, Denmark | $145,000 | 29,288 | Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| bausch.com | 1853 | Bridgewater, United States | – | 1,681 | Ophthalmic pharmaceuticals and instruments are developed for eye care. | |
| astrazeneca.com | 1913 | Cambridge, United Kingdom | – | 83,100 | Pharmaceutical and biologics products are developed and distributed worldwide. | |
| sanofi.com | 1973 | Paris, France | – | 1,006,566 | Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. |
Detailed competitors of Noven
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Noven
The website of Noven (noven.com) receives about 7.2K visits a month and ranks #3,107,578 among all websites worldwide, #4,106 in Biotechnology and Pharmaceuticals.
- Monthly visits7.2K
▲ 9.8% vs previous month
- Unique visitors3.1K
per month
- Global rank#3,107,578
among all websites
- Category rank#4,106
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.7
- Average visit1 min 09 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Noven. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
llorenspharm.com | llorenspharm.com | 100% | – | – | – |
| catalystpharma.com | 91% | 8.9K | #2,466,713 | View details | |
cebert.com | cebert.com | 84% | – | – | – |
| xstalbio.com | 83% | – | – | View details | |
| smblab.be | 83% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 28 similar websites and full traffic analytics for Noven
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 28 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Noven
Complete news archive for Noven
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Noven
10 companies that operate in the same segment as Noven (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Noven
Noven was founded in 1987.
Noven is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
Noven has 291 employees.
Noven Pharmaceuticals, Inc. is recognized as a fully integrated specialty pharmaceutical company with expertise in transdermal drug delivery systems. Products are developed and offered in the therapeutic areas of mental health and womens health, addressing specific patient needs through innovative technologies. Strategic partnerships are maintained to enhance product reach and development capabilities. The company is committed to benefiting patients and physicians by setting standards of excellence in manufacturing and delivery solutions within the healthcare sector.
Noven's top competitors include Merck, Roivant Sciences and AbbVie.
Noven offers XELSTRYM, SECUADO, DAYTRANA, MINIVELLE, and COMBIPATCH.
Noven has made 2 acquisitions, including JDS Pharmaceuticals, and JDS Therapeutics.
Noven has 1 investor. Key investors include Hisamitsu Pharmaceutical.
Noven operates through Noven Pharmaceuticals, Inc..
Yes. Noven was acquired by Hisamitsu Pharmaceutical in July 2009.